These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34733843)

  • 61. Pan-cancer analysis of
    Jiang T; Chen X; Su C; Ren S; Zhou C
    J Cancer; 2020; 11(4):776-780. PubMed ID: 31949479
    [No Abstract]   [Full Text] [Related]  

  • 62. Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma.
    Li J; Li H; Zhang C; Zhang C; Jiang L; Wang H; Liu H
    Front Oncol; 2021; 11():732841. PubMed ID: 34631565
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
    Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
    ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of Key Pathways and Genes Related to Immunotherapy Resistance of LUAD Based on WGCNA Analysis.
    Yu W; Liu F; Lei Q; Wu P; Yang L; Zhang Y
    Front Oncol; 2021; 11():814014. PubMed ID: 35071018
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma.
    Lin W; Wang X; Wang Z; Shao F; Yang Y; Cao Z; Feng X; Gao Y; He J
    Front Cell Dev Biol; 2021; 9():780461. PubMed ID: 34869385
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Homozygous deletion of the
    Zhang H; Dong W; Zhao H; Zeng Z; Zhang F; Hu Y; Li Q; Chen J; Meng E; Xiao W
    Ann Transl Med; 2021 Oct; 9(19):1506. PubMed ID: 34805368
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Prognostic Value of a Tumor Microenvironment-Based Immune Cell Infiltration Score Model in Colon Cancer.
    Tang X; Liu M; Luo X; Zhu M; Huang S; Pan X
    Front Oncol; 2021; 11():728842. PubMed ID: 34737949
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers.
    Romero JM; Titmuss E; Wang Y; Vafiadis J; Pacis A; Jang GH; Zhang A; Golesworthy B; Lenko T; Williamson LM; Grünwald B; O'Kane GM; Jones SJM; Marra MA; Wilson JM; Gallinger S; Laskin J; Zogopoulos G
    NPJ Precis Oncol; 2023 Aug; 7(1):73. PubMed ID: 37558751
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advancing the Boundaries of Immunotherapy in Lung Adenocarcinoma with Idiopathic Pulmonary Fibrosis by a Biomimetic Proteinoid Enabling Selective Endocytosis.
    Jiang A; Zheng X; Yan S; Yan J; Yao Y; He W
    ACS Nano; 2024 Feb; 18(7):5358-73. PubMed ID: 38319028
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma.
    Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Li C; He J
    Front Oncol; 2022; 12():828814. PubMed ID: 35392225
    [TBL] [Abstract][Full Text] [Related]  

  • 71. NF1 mutations as biomarker of response to immune checkpoint blockades for lung adenocarcinoma patients.
    Giraud JS; Jouinot A; Pasmant E; Tlemsani C
    NPJ Precis Oncol; 2024 Feb; 8(1):32. PubMed ID: 38341500
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
    Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
    Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predictive Value of Max's Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Qu Y; Wang C; Liu L; Li S; Zhang X; Ma Z; Bai H; Wang J
    Front Cell Dev Biol; 2021; 9():728647. PubMed ID: 34733843
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.
    Liu M; Yang M; Zhang B; Xia S; Zhao J; Yan L; Ren Y; Guo H; Zhao J
    J Mol Med (Berl); 2024 Jul; 102(7):899-912. PubMed ID: 38739269
    [TBL] [Abstract][Full Text] [Related]  

  • 77. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
    Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
    Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.